Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology.
Yaping SunLingyun WangPublished in: Pharmaceuticals (Basel, Switzerland) (2024)
The efforts to discover HIV therapeutics have continued since the first human immunodeficiency virus (HIV) infected patient was confirmed in the 1980s. Ten years later, the first HIV drug, zidovudine (AZT), targeting HIV reverse transcriptase, was developed. Meanwhile, scientists were enlightened to discover new drugs that target different HIV genes, like integrase, protease, and host receptors. Combination antiretroviral therapy (cART) is the most feasible medical intervention to suppress the virus in people with HIV (PWH) and control the epidemic. ART treatment has made HIV a chronic infection rather than a fatal disease, but ART does not eliminate latent reservoirs of HIV-1 from the host cells; strict and life-long adherence to ART is required for the therapy to be effective in patients. In this review, we first discussed the scientific history of conventional HIV drug discovery since scientists need to develop more and more drugs to solve drug-resistant issues and release the side effects. Then, we summarized the novel research technologies, like gene editing, applied to HIV treatment and their contributions to eliminating HIV as a complementary therapy.
Keyphrases
- antiretroviral therapy
- hiv infected
- human immunodeficiency virus
- hiv positive
- hiv aids
- hiv infected patients
- hiv testing
- hepatitis c virus
- men who have sex with men
- drug resistant
- healthcare
- drug discovery
- stem cells
- emergency department
- skeletal muscle
- cystic fibrosis
- type diabetes
- gene expression
- end stage renal disease
- peritoneal dialysis
- cancer therapy
- insulin resistance
- cell proliferation
- dna methylation
- newly diagnosed
- adipose tissue
- ejection fraction
- drug delivery
- adverse drug
- weight loss